Global Lumakras (Sotorasib) Market Overview: Strategies for 2030

According to the study by Next Move Strategy Consulting, the Lumakras (Sotorasib) Market is witnessing robust growth, driven by its breakthrough role as the first FDA-approved KRAS inhibitor for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Factors driving the lumakras (sotorasib) market growth are the ever-increasing cases of cancer and the high mortality due to it. 

The lumakras (sotorasib) market is segmented by dose, by application and by geography. Based on type the market is divided into 960 mg, 480 mg and 240 mg.

Request for a FREE Sample PDF : https://www.nextmsc.com/lumakras-sotorasib-market/request-sample